Where the stock stands
Acutaas Chemicals Ltd. is carried in Strota's data under the Healthcare sector, with a market capitalisation of ₹27,766 crore. The stock closed at ₹3,198.2 on 17 August 2026, and the most recent quote in the pack is ₹3,391.4 — a rise of 6.04% against that close. The same reading has the Nifty down 0.87%, so the gain came on a day the wider market was lower, not with it.
Stretch the window and the picture is one of a long run followed by a pause. Measured to the 17 August close, the stock is up 145.26% over a year and sits 148.35% above its 52-week low of ₹1,287.8, while still 14.49% under its 52-week high of ₹3,740. The nearer horizons are softer: down 2.55% over a week and 11.63% over a month, against a three-month gain of 11.02%. On the reported earnings base of ₹34.94 per share the price-to-earnings ratio is 97.06, price-to-book is 16.8, and the dividend yield is 0.04%. Those are the multiples the data reports; the pack carries no growth or margin history to set them against, so they are a description rather than a verdict.
What the smart-money flow shows
This is normally the most informative part of a stock's file, and here it is empty. The pack holds no futures or options positioning for the stock — no long buildup, meaning fresh futures positions opened while the price rises, and no short buildup either. It records no bulk or block deals, the large negotiated trades an exchange discloses with the counterparty named. It records no insider filings, and no run of institutional buying or selling. That absence is itself the finding: the 6.04% move has no identified buyer behind it in this data, and nothing here places a professional or promoter footprint on either side of it.
The one adjacent clue is participation. Relative volume — a session's turnover set against the stock's own recent norm — reads 0.45 in the technicals dated 17 August, less than half a typical day. That figure describes the session before the latest quote, so it says the run-in was quiet; it says nothing about turnover on the move itself.
The technical picture
The trend indicators are split. The close sits above the 200-day moving average but below the 50-day, the usual signature of a stock in a longer uptrend working through a shorter-term setback. Neither a golden cross nor a death cross — the 50-day average crossing up through or down below the 200-day — is flagged in the record.
Momentum is neutral to soft. The 14-day relative strength index, which weighs recent up moves against recent down moves, reads 44.7: below the midpoint of its range, and at neither the oversold nor the overbought extreme. Read alongside the one-month decline of 11.63% and the 14.49% distance from the high, the technicals describe consolidation rather than either breakdown or breakout.
Catalysts and what to watch
The headline record is thin and mostly procedural. According to a headline from scanx.trade about ten days before this data was compiled, the company scheduled investor meetings in Singapore and Mumbai. A GuruFocus.com headline roughly three weeks earlier pointed to highlights from a first-quarter FY27 earnings call and characterised the growth as robust; that is the headline's framing, not something the pack's own numbers confirm. The older items are price and volume reports rather than events: Business Standard headlines noted a surge in volumes at the counter and, some months back, the stock leading losers in the exchange's 'A' group, while a Univest headline recorded a fall of 2.29% on its day.
What the data establishes is narrow: a stock far above its 52-week low and still below its high, expensive on reported earnings, technically mid-range, and up 6.04% on its latest print while the index fell. What it does not establish is why. There is no flow data, no deal record, no insider trail and no confirmed corporate event in this pack to explain the move, and nothing scheduled in it beyond the reported investor meetings.